

PA (UYDU-) UNIV DUKE.
 PI Kornbluth SA, Holley C;
 XX WPI: 2002-241769/29.
 DR N-PSDB; AAD31598.
 XX
 PT New human homologue of Drosophila melanogaster reaper protein (hrpr),
 PT useful for generating antibodies and for screening compounds, which can
 PT inhibit or enhance hrpr activity -
 XX
 PS Claim 1; Fig 1; 45pp; English.
 XX
 CC The invention relates to human homologue of Drosophila melanogaster
 CC Reaper protein (hrpr) and its corresponding nucleic acid. The hrpr
 CC polypeptides are useful for generating antibodies, which can be used
 CC in detection or purification protocols designed to detect or purify
 CC the polypeptide to which the antibody is directed. These sequences
 CC are also used for screening compounds, which can enhance or inhibit
 CC hrpr and for treating tumours. The hrpr polynucleotides are useful
 CC as a probe or primer. The present sequence is human homologue of
 CC Drosophila melanogaster reaper protein (hrpr).
 CC
 SQ Sequence 81 AA:
 Query Match 100.0%; Score 81; DB 23; Length 81;
 Best Local Similarity 100.0%; Pred. No. 3.2e-77;
 Matches 81; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MLSTHFLYFLYFLYSYSGDRAKCLRTKQKQKQKQILROSEVLFRESETLRTKKG 60
 DB 1 MLSTHFLYFLYFLYSYSGDRAKCLRTKQKQKQKQILROSEVLFRESETLRTKKG 60
 QY 61 RRMGGGCGRGCTADTGSMFLS 81
 DB 61 RRMGGGCGRGCTADTGSMFLS 81
 RESULT 2
 ID AAE19842 standard; peptide: 20 AA.
 AC AAE19842;
 DT 18-JUN-2002 (first entry)
 DE Human hrpr derived peptide.
 DE Human hrpr derived peptide.
 KW Human: reaper protein; Rpr; detection; purification; screening;
 KW therapy; tumour; cytostatic.
 OS Homo sapiens.
 PN WO200212540-A2.
 PD 14-FEB-2002.
 XX 08-AUG-2001; 2001WO-US24765.
 PR 08-AUG-2000; 2000US-223699P.
 PA (UYDU-) UNIV DUKE.
 PI Kornbluth SA, Holley C;
 XX WPI: 2002-241769/29.
 DR
 XX New human homologue of Drosophila melanogaster reaper protein (hrpr),
 PT useful for generating antibodies and for screening compounds, which can
 PT inhibit or enhance hrpr activity -
 XX
 PS Example 1; Page 19; 45pp; English.

CC The invention relates to human homologue of Drosophila melanogaster
 CC Reaper protein (hrpr) and its corresponding nucleic acid. The hrpr
 CC polypeptides are useful for generating antibodies, which can be used
 CC in detection or purification protocols designed to detect or purify
 CC the polypeptide to which the antibody is directed. These sequences
 CC are also used for screening compounds, which can enhance or inhibit
 CC hrpr and for treating tumours. The hrpr polynucleotides are useful
 CC as a probe or primer. The present sequence is human homologue of
 CC Drosophila melanogaster reaper protein (hrpr) derived peptide.
 CC
 SQ Sequence 20 AA:
 Query Match 21.0%; Score 17; DB 23; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.3e-10;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 39 QILROSEVLFRESETLRK 55
 DB 4 QILROSEVLFRESETLRK 20
 RESULT 3
 ID AAG02507 standard; Protein: 71 AA.
 AC AAG02507;
 DT 06-OCT-2000 (first entry)
 DE Human secreted protein, SEQ ID NO: 6588.
 DE Human: 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
 KW gene therapy; chromosome mapping.
 OS Homo sapiens.
 PN EP1033401-A2.
 PD 06-SEP-2000. *Not out*
 XX 21-FEB-2000; 2000EP-0200610.
 PR 26-FEB-1999; 99US-0122487.
 PA (GEST) GENSET.
 PI Dumas Milne Edwards J, Duclet A, Giordano J;
 DR WPI: 2000-500381/45.
 DR N-PSDB; AAC02513.
 XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for
 PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
 PT diagnostic, forensic, gene therapy and chromosome mapping procedures -
 XX
 PS Claim 13; SEQ ID 6588; 71pp + CD-ROM; English.
 XX The present sequence is a polypeptide encoded by one of a large number
 CC of 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs
 CC were prepared from total human RNAs or polyA+ RNAs derived from 30
 CC different tissues. EST sequences usually correspond mainly to the 3'
 CC untranslated region (UTR) of the mRNA because they are often obtained
 CC from oligo-dT primed cDNA libraries. Such ESTs are not well suited for
 CC isolating cDNA sequences derived from the 5' ends of mRNAs and even in
 CC those cases where longer cDNA sequences have been obtained, the full 5'
 CC UTR is rarely included. 5' ESTs are derived from mRNAs with intact 5'
 CC ends and can therefore be used to obtain full length cDNAs and genomic
 CC DNAs. 5' ESTs are also used in diagnostic, forensic, gene therapy and
 CC chromosome mapping procedures. They are used to obtain upstream
 CC regulatory sequences and to design expression and secretion vectors.
 XX
 SQ Sequence 71 AA;

Query Match 13.6%; Score 11; DB 21; Length 71;
Best Local Similarity 100.0%; Pred. No. 0.00073;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 7 LFYLFYFUS 17
Db 14 LFYLFYFUS 24

RESULT 4

AA002957
ID AA002957 standard; Protein: 117 AA.
AC AA002957;
XX
DT 06-NOV-2001 (first entry)
DE Human polypeptide SEQ ID NO 16849.
XX
XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation.
XX
OS Homo sapiens.
XX
PN WO200164835-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US04927.
XX
PR 28-FEB-2000; 2000US-0515126.
PR 18-MAY-2000; 2000US-0577409.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI: 2001-514838/56.
DR N-PSDB; AA162886.
XX
XX Isolated nucleic acids and polypeptides, useful for preventing
PT diagnosing and treating e.g. leukaemia, inflammation and immune
PT disorders -
XX
PS Claim 20; SEQ ID NO 16849; 1399pp + Sequence Listing; English.

XX The invention relates to human polynucleotides (AA179941-AA193841) and
CC the encoded proteins (AA000010-AA013910) that exhibit activity relating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activity/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at [ftp.wipo.int/pub/published_pcl_sequences](http://wipo.int/pub/published_pcl_sequences).
XX
SQ Sequence 117 AA;

Query Match 12.3%; Score 10; DB 22; Length 117;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 19 SLGDRARICL 28
Db 15 SLGDRARICL 24

RESULT 5
AAU29487
ID AAU29487 standard; Protein: 181 AA.
XX
AC AAU29487;
XX
DT 18-DEC-2001 (first entry)
DE Human G protein-coupled receptor (GPCR) polypeptide #108.
XX
DE Human; G protein-coupled receptor; GPCR; mental disorder; schizophrenia;
KW neurological disorder; metabolic disorder; cancer; rheumatoid arthritis;
KW thyroid disorder; neurodegenerative disorder; cardiovascular disorder;
KW renal failure; autoimmune disorder; hyperproliferative disorder; HIV;
KW human immunodeficiency virus; viral infection; neuroprotective;
KW immunostimulant; neuroleptic; nootropic; tranquiliser; antidepressant;
KW anorectic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200168658-A2.
XX
PD 20-SEP-2001.
XX
PF 16-MAR-2001; 2001WO-US08456.
XX
PR 16-MAR-2000; 2000US-187783P.
PR 16-MAR-2000; 2000US-189907P.
PR 16-MAR-2000; 2000US-189917P.
PR 16-MAR-2000; 2000US-189918P.
PR 16-MAR-2000; 2000US-189960P.
PR 29-MAR-2000; 2000US-192155P.
PR 29-MAR-2000; 2000US-192234P.
PR 29-MAR-2000; 2000US-192830P.
PR 29-MAR-2000; 2000US-192916P.
PR 29-MAR-2000; 2000US-192923P.
PR 29-MAR-2000; 2000US-192933P.
PR 29-MAR-2000; 2000US-192945P.
XX
PA (PHAA) PHARMACIA & UPJOHN CO.
XX
PI Vogel I G;
XX
DR WPI: 2001-607458/69.
DR N-PSDB; AAS46926.
XX
XX Nucleic acid encoding G protein-coupled receptors, useful for the
PT prevention, diagnosis and treatment of mental disorders -
XX
PS Claim 31; Page 94; 274pp; English.

XX Sequences AAU29380-AAU29509 represent human G protein-coupled receptor
CC (GPCR) polypeptides of the invention. The proteins and the DNA sequences
CC encoding them can be used to identify compounds which bind to GPCR
CC polypeptides and in screening for compounds that modulate GPCR activity.
CC By screening a human subject for the presence of mutations in GPCR DNA, a
CC GPCR-related disorder or a genetic predisposition can be diagnosed. The
CC sequences can also be used for treatment and prevention of mental
CC disorders such as schizophrenia, neurological disorders such as manic
CC depression, metabolic disorders such as obesity, cancer, rheumatoid
CC arthritis, thyroid disorders such as myxoedema, neurodegenerative
CC disorders such as Parkinson's disease, cardiovascular disorders such as
CC atherosclerosis, renal failure, autoimmune disorders, hyperproliferative
CC disorders such as psoriasis and viral infections such as those caused by
CC HIV.
XX
SQ Sequence 181 AA;

Query Match 12.3%; Score 10; DB 22; Length 181;
Best Local Similarity 100.0%; Pred. No. 0.018;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 SLGDRARLCL 28
 DB 1 SLGDRARLCL 10
 RESULT 6
 ABG60775
 ID ABG60775 standard; Protein; 181 AA.
 XX
 XX ABG60775;
 XX
 DT 13-AUG-2002 (first entry)
 XX
 DE Novel G protein coupled receptor (ngPCR-x) #108.
 XX
 KW G protein coupled receptor; ngPCR-x; immune response; thyroid disorder;
 KW mental disorder; rheumatoid arthritis; myxedema; inflammatory condition;
 KW Crohn's disease; cell differentiation; homeostasis; rheumatoid arthritis;
 KW renal failure; autoimmune disorder; movement disorder; CNS disorder;
 KW viral infection; human immunodeficiency virus; HIV; metabolic disorder;
 KW cardiovascular disorder; diabetes; obesity; anorexia; cardiomyopathy;
 KW proliferative disease; cancer; psoriasis; lung cancer; hormonal disorder;
 KW sexual dysfunction.
 XX
 OS Homo sapiens.
 PN US2002058306-A1.
 XX
 PD 16-MAY-2002.
 XX
 PF 16-MAR-2001; 2001US-0811284.
 XX
 PR 16-MAR-2000; 2000US-189783P.
 PR 16-MAR-2000; 2000US-189907P.
 PR 16-MAR-2000; 2000US-189917P.
 PR 16-MAR-2000; 2000US-189918P.
 PR 16-MAR-2000; 2000US-189960P.
 PR 24-MAR-2000; 2000US-192153P.
 PR 27-MAR-2000; 2000US-192233P.
 PR 29-MAR-2000; 2000US-192830P.
 PR 29-MAR-2000; 2000US-192945P.
 PR 29-MAR-2000; 2000US-192916P.
 PR 29-MAR-2000; 2000US-192923P.
 PR 29-MAR-2000; 2000US-192830P.
 PR 29-MAR-2000; 2000US-192945P.
 PR 29-MAR-2000; 2000US-192830P.
 PR 29-MAR-2000; 2000US-192945P.
 PR 29-MAR-2000; 2000US-192830P.
 PR 29-MAR-2000; 2000US-192945P.
 PA (VOGE/) VOGELI G.
 XX
 PI VogelI G;
 XX
 DR WPI: 2002-434856/46.
 DR N-PSDB; ABR81704.
 XX
 XX
 PT New isolated nucleic acid encoding a G protein coupled receptor for
 PT producing the receptor which can induce an immune response in a mammal
 PT
 PT
 PS Claim 27; Page 72; 216pp; English.
 XX
 XX The invention describes an isolated nucleic acid (I) comprising a
 CC sequence encoding a portion of a G protein coupled receptor (ngPCR-x).
 CC (I) is used to produce a recombinant ngPCR-x polypeptide. A polypeptide
 CC encoded by (I) is used to induce an immune response in a mammal. ngPCR-x
 CC is used to identify a compound that binds to it and/or modulates it's
 CC activity. (I) is used to identify animal homologues of ngPCR-x. (I) can
 CC be used to diagnose a human subject as having a brain or genetic
 CC predisposition disorder, such as a mental disorder. (I) is used to
 CC screen for an ngPCR-x related disorder including thyroid disorders (e.g.
 CC thyrotoxicosis, myxedema), renal failure, inflammatory conditions (e.g.

CC Crohn's disease), diseases related to cell differentiation and
 CC homeostasis, rheumatoid arthritis, autoimmune disorders, movement
 CC disorders, CNS disorders, viral infections (e.g. Human immunodeficiency
 CC virus), metabolic and cardiovascular disorders (e.g. diabetes, obesity,
 CC anorexia, cardiomyopathies), proliferative diseases and cancers (e.g.
 CC psoriasis, lung cancer), hormonal disorders, sexual dysfunction and
 CC hereditary mental disorders in a human patient. A host cell comprising
 CC (I) is used to screen for a modulator of ngPCR-x activity. ngPCR-x is
 CC used to identify compounds that can treat mental disorders. The
 CC polypeptide encoded by (I) is used to purify a G protein from a sample.
 CC This is the amino acid sequence of a novel G protein coupled receptor
 CC (ngPCR-x) protein described in the invention.
 XX
 XX Sequence 181 AA;
 SQ
 Query Match 12.3%; Score 10; DB 23; Length 181;
 Best Local Similarity 100.0%; Pred. No. 0.018;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 19 SLGDRARLCL 28
 DB 1 SLGDRARLCL 10
 RESULT 7
 AAB34577
 ID AAB34577 standard; Protein; 29 AA.
 XX
 AC AAB34577;
 XX
 DT 26-JAN-2001 (first entry)
 XX
 DE Human secreted protein sequence encoded by gene 1 SEQ ID NO:61.
 XX
 KW Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;
 KW antirheumatic; antiproliferative; cytostatic; cardiant; vasotropic;
 KW cerebroprotective; neurotrophic; neuroprotective; antibacterial; vitruclide;
 KW fungicide; ophthalmological; gene therapy; autoimmune disease; neoplasm;
 KW hyperproliferative disorder; cancer; cardiovascular disorder; infection;
 KW cerebrovascular disorder; angiogenesis; nervous system disorder;
 KW ocular disorder; wound healing; skin aging; food additive; preservative.
 XX
 OS Homo sapiens.
 PN WO200056751-A1.
 XX
 PD 28-SEP-2000.
 XX
 PF 09-MAR-2000; 2000MO-US06013.
 XX
 PR 19-MAR-1999; 99US-0125360.
 PR 11-JUN-1999; 99US-0138626.
 PR 03-DEC-1999; 99US-0168662.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Ruben SM, Komatsoulis G;
 XX
 DR WPI: 2000-579482/54.
 DR N-PSDB; AAC59738.
 XX
 XX
 PT Isolated nucleic acid molecule encoding a human secreted protein is
 PT used in preventing, treating or ameliorating a medical condition
 PT
 PT
 PS Claim 11; Page 371; 419pp; English.
 XX
 XX The polynucleotide sequences given in AAC59738 to AAC59787 encode the
 CC human secreted proteins given in AAB34577 to AAB34626. AAB34627 to
 CC AAB34686 represent human secreted polypeptide sequences and proteins
 CC homologous to them, which are given in the exemplification of the present
 CC invention. Human secreted proteins have activities based on the tissues
 CC and cells the genes are expressed in. Example of activities include:
 CC antarthritic; immunosuppressive; antirheumatic; antiproliferative;

CC cytosolic; cardiant; vasotropic; cerebroprotective; nootropic;
CC neuroprotective; antibacterial; virucide; fungicide; and
CC ophthalmological. The polynucleotides and proteins can be are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also
CC used in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Disorders which are diagnosed or treated include
CC autoimmune diseases, hyperproliferative disorders e.g. neoplasms and
CC cancers of the breast or liver, cardiovascular disorders,
CC cerebrovascular disorders, angiogenesis, nervous system disorders,
CC infections caused by bacteria, viruses and fungi and ocular disorders.
CC The proteins can also be used to aid wound healing and epithelial cell
CC proliferation, to prevent skin aging due to sunburn, to maintain organs
CC before transplantation, for supporting cell culture of primary tissues,
CC to regenerate tissues and in chemotaxis. The proteins can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities. AAC59729 to AAC59737 and AAB34576 represent sequences used
CC in the exemplification of the present invention.

XX Sequence 29 AA;

SO Query Match

Best Local Similarity 11.18; Score 9; DB 21; Length 29;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 7 LFTYLFYIF 15

Db 18 LFTYLFYIF 26

RESULT 8

AA085158 standard; Protein; 39 AA.

XX AA085158;

DT 07-NOV-2001 (first entry)

DE Human immune/haematopoietic antigen SEQ ID NO:12751.

XX Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;

KW cytosolic; gene therapy; vaccine; metastasis.

XX Homo sapiens.

PN W0200157182-A2.

XX 09-AUG-2001.

PF 17-JAN-2001; 2001WO-US01354.

XX 31-JAN-2000; 2000US-0179065.

PR 04-FEB-2000; 2000US-0180628.

PR 24-FEB-2000; 2000US-0184664.

PR 02-MAR-2000; 2000US-0186350.

PR 16-MAR-2000; 2000US-0189874.

PR 17-MAR-2000; 2000US-0190076.

PR 18-APR-2000; 2000US-0198123.

PR 19-MAY-2000; 2000US-0203515.

PR 28-JUN-2000; 2000US-0209467.

PR 30-JUN-2000; 2000US-0215135.

PR 07-JUL-2000; 2000US-0216647.

PR 07-JUL-2000; 2000US-0216880.

PR 11-JUL-2000; 2000US-0217487.

PR 14-JUL-2000; 2000US-0218290.

PR 26-JUL-2000; 2000US-0220963.

PR 26-JUL-2000; 2000US-0220964.

PR 14-AUG-2000; 2000US-0224518.

PR 14-AUG-2000; 2000US-0224519.

PR 14-AUG-2000; 2000US-0225213.

PR 14-AUG-2000; 2000US-0225214.

PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 16-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 27-SEP-2000; 2000US-0235837.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.

Db 3 LEIYLFIFY 11

RESULT 10

ABP10360

XX AAB10360 standard; Protein: 57 AA.

AC

XX AAB10360;

XX

DT 24-JUN-2002 (first entry)

XX

DE Human ORFX protein sequence SEQ ID NO:20702.

XX

KM Human: open reading frame; ORFX: gene therapy; cancer; cirrhosis;

KM hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;

KM degenerative disorder; osteoarthritis; neurodegenerative disorder;

KM cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;

KM hypertension; hypothyroidism; cholesterol ester storage disease;

KM immune deficiency; immune disorder; infectious disease;

KM autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;

KM myasthenia gravis.

XX

OS Homo sapiens.

XX

PN WO200192523-A2.

XX

PD 06-DEC-2001.

XX

PE 29-MAY-2001; 2001WO-US10836.

XX

PR 30-MAY-2000; 2000US-206132P.

XX

PR 29-AUG-2000; 2000US-228716P.

XX

PA (CURA-) CURAGEN CORP.

XX

PI Shimkets RA, Leach MD;

XX

DR WPI: 2002-106308/14.

DR N-PSDB; AABN26112.

XX

PT Novel human polypeptides and polynucleotides useful for diagnosing,

PT preventing and treating cardiovascular disease, neurodegenerative,

PT hyperproliferative disorders and autoimmune disorders

XX

PS Disclosure; SEQ ID 20702; 1037pp; English.

XX

CC The present invention describes substantially purified human proteins

CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1

CC in the specification). AABN15762 to AABN27252 encode the human ORFX

CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for

CC treating or preventing a pathology associated with an ORFX-associated

CC disorder in humans, and in the manufacture of a medicament for treating a

CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide

CC sequences can be used in gene therapy. ORFX sequences can be used in the

CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,

CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,

CC osteoarthritis, neurodegenerative disorders, disorders related to organ

CC transplantation, cardiovascular diseases, diabetes mellitus, systemic

CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester

CC storage disease, various immune deficiencies and disorders, infectious

CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid

CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host

CC disease and autoimmune inflammatory eye disease. ORFX proteins are also

CC useful for treating burns, incisions, ulcers, for treating osteoporosis,

CC bone degenerative disorders, or periodontal disease, and for gut

CC protection or regeneration and treatment of lung or liver fibrosis,

CC reperfusion injury in various tissues and conditions resulting from

CC systemic cytokine damage.

CC N.B. The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at [ftp.wipo.int/pub/published_pct_sequences](http://wipo.int/pub/published_pct_sequences).

XX

XX Sequence 57 AA;

Query Match 11.1%; Score 9; DB 23; Length 57;

Best Local Similarity 100.0%; Pred. No. 0.076;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 7 LEIYLFIFY 15

|||||||

Db 40 LEIYLFIFY 48

RESULT 11

AAB58270

XX AAB58270 standard; Protein: 77 AA.

XX

AC AAB58270;

XX

DT 14-MAR-2001 (first entry)

XX

DE Lung cancer associated polypeptide sequence SEQ ID 608.

XX

KM Human: lung cancer associated protein; neuroprotective; cytostatic;

KM cardioactive; immunomodulatory; muscular active; vulnery;

KM gastrointestinal; nephrotoxic; antiinfective; gynecological;

KM antibacterial; diagnosis; neural disorder; immune disorder; reproductive;

KM proliferative disorder; wound healing; infectious disease.

XX

OS Homo sapiens.

XX

PN WO200055180-A2.

XX

PD 21-SEP-2000.

XX

PE 08-MAR-2000; 2000WO-US05918.

XX

PR 12-MAR-1999; 99US-0124270.

XX

PA (HUMA-) HUMAN GENOME SCI INC.

XX

PA (ROSE/) ROSEN C A.

XX

PI Ruben SM;

XX

DR WPI: 2000-587514/55.

DR N-PSDB; AAF18146.

XX

PT Lung cancer associated gene sequences, referred to as lung cancer

PT antigens, useful for treatment, prevention, and diagnosis of disorders

PT such as lung cancer

XX

PS Claim 11; Page 1100; 1425pp; English.

XX

CC Polynucleotide sequences AAF17982 - AAF18424 encode human lung cancer

CC associated proteins represented in AAB58106 - AAB58548. Lung cancer

CC associated proteins and polynucleotide sequences, their agonists, and

CC antagonists may have neuroprotective; cytostatic; cardioactive;

CC immunomodulatory; muscular active general; vulnery; gastrointestinal

CC general; nephrotoxic; antiinfective; gynecological; or antibacterial

CC activity. The invention also includes antibodies specific for the

CC protein or polynucleotide sequences. The lung cancer associated

CC polynucleotide sequences may be used for detection of lung cancer,

CC chromosome identification, as chromosome markers, and for numerous other

CC diagnostic or research purposes. The proteins may be used to treat

CC disorders such as neural, immune, muscular, reproductive,

CC gastrointestinal, pulmonary, cardiovascular, renal, and proliferative

CC disorders. The proteins may also be used in the treatment of wounds and

CC infectious diseases. Polynucleotide sequences AAF18425 - AAF18433 and

CC peptide AAB58549 are used in the course of the invention for the

CC identification and characterisation of the polynucleotide and protein

CC sequences.

XX

XX Sequence 77 AA;

XX

Query Match 11.1%; Score 9; DB 21; Length 77;

Best Local Similarity 100.0%; Pred. No. 0.098;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 HLFYLFYF 14
| | | | | | | |
Db 13 HLFYLFYF 21

RESULT 12
AAO06842
ID AAO06842 standard; Protein: 82 AA.
XX
AC AAO06842;

DT 06-NOV-2001 (first entry)

DE Human polypeptide SEQ ID NO 20734.

KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation.

OS Homo sapiens.

PN WO200164835-A2.

PD 07-SEP-2001.

PE 26-FEB-2001; 2001WO-US04927.

PF 28-FEB-2000; 2000US-0515126.

PR 18-MAY-2000; 2000US-0577409.

PA (HYSE-) HYSEQ INC.

PI Tang YT, Liu C, Drmanac RT;

DR WPI; 2001-514838/56.

DR N-PSDB; AA186773.

PT Isolated nucleic acids and polypeptides, useful for preventing
PT diagnosing and treating e.g. leukaemia, inflammation and immune
PT disorders -

PS Claim 20; SEQ ID NO 20734; 1399pp + Sequence Listing; English.

CC The invention relates to human polynucleotides (AA179941-AA193841) and
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.

SO Sequence 82 AA;

Query Match 11.1%; Score 9; DB 22; Length 82;

Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 YSLGDRARL 26
| | | | | | | |
Db 38 YSLGDRARL 46

RESULT 13

AAO10269
ID AAO10269 standard; Protein: 88 AA.
XX
AC AAO10269;

DT 06-NOV-2001 (first entry)

DE Human polypeptide SEQ ID NO 24161.

KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation.

OS Homo sapiens.

PN WO200164835-A2.

PD 07-SEP-2001.

PE 26-FEB-2001; 2001WO-US04927.

PF 28-FEB-2000; 2000US-0515126.

PR 18-MAY-2000; 2000US-0577409.

PA (HYSE-) HYSEQ INC.

PI Tang YT, Liu C, Drmanac RT;

DR WPI; 2001-514838/56.

DR N-PSDB; AA190200.

PT Isolated nucleic acids and polypeptides, useful for preventing
PT diagnosing and treating e.g. leukaemia, inflammation and immune
PT disorders -

PS Claim 20; SEQ ID NO 24161; 1399pp + Sequence Listing; English.

CC The invention relates to human polynucleotides (AA179941-AA193841) and
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.

SO Sequence 88 AA;

Query Match 11.1%; Score 9; DB 22; Length 88;

Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 LFLYLFYF 15
| | | | | | | |
Db 41 LFLYLFYF 49

Db 41 LFLYLFYF 49

RESULT 14
ABG10494
ID ABG10494 standard; Protein: 115 AA.

AC ABG10494;

DT 13-FEB-2002 (first entry)

DE Novel human diagnostic protein #10485.

XX Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX Homo sapiens.
 OS WO200175067-A2.
 XX PD 11-OCT-2001.
 XX PF 30-MAR-2001; 2001WO-US08631.
 XX PR 31-MAR-2000; 2000US-0540217.
 XX PR 23-AUG-2000; 2000US-0649167.
 XX PA (HYSE-) HYSEQ INC.
 PL Dimaenac RT, Liu C, Tang YT;
 PI WPI; 2001-639362/73.
 DR N-PSDB; AAS74681.
 XX New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity -
 XX Claim 20; SEQ ID No 40853; 103bp; English.
 PS The invention relates to isolated polynucleotide (I) and
 XX polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG30377 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pcl_sequences.
 XX Sequence 115 AA;
 SQ
 Query Match 11.1%; Score 9; DB 22; Length 115;
 Best Local Similarity 100.0%; Pred. No. 0.14;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 20 LGDRAIRLCL 28
 DB 65 LGDRAIRLCL 73
 RESULT 15
 AAM96077
 ID AAM96077 standard; Protein: 120 AA.
 XX AAM96077;
 AC AAM96077;
 XX 21-NOV-2001 (first entry)
 DT Human reproductive system related antigen SEQ ID NO: 4735.
 DE Human reproductive system related antigen; reproductive system disorder;
 XX Human; reproductive system related antigen; reproductive system disorder;

KW cancer; gene therapy.
 XX Homo sapiens.
 OS WO20015320-A2.
 XX PD 02-AUG-2001.
 XX PF 17-JAN-2001; 2001WO-US01339.
 XX PR 31-JAN-2000; 2000US-0179065.
 XX PR 04-FEB-2000; 2000US-0180628.
 XX PR 24-FEB-2000; 2000US-0184664.
 XX PR 02-MAR-2000; 2000US-0186350.
 XX PR 16-MAR-2000; 2000US-0189874.
 XX PR 17-MAR-2000; 2000US-0190076.
 XX PR 18-APR-2000; 2000US-0198123.
 XX PR 19-MAY-2000; 2000US-0205515.
 XX PR 07-JUN-2000; 2000US-0209467.
 XX PR 28-JUN-2000; 2000US-0214886.
 XX PR 30-JUN-2000; 2000US-0215135.
 XX PR 07-JUL-2000; 2000US-0216647.
 XX PR 07-JUL-2000; 2000US-0216880.
 XX PR 11-JUL-2000; 2000US-0217487.
 XX PR 14-JUL-2000; 2000US-0217496.
 XX PR 26-JUL-2000; 2000US-0218290.
 XX PR 26-JUL-2000; 2000US-0220963.
 XX PR 14-AUG-2000; 2000US-0220964.
 XX PR 14-AUG-2000; 2000US-0224518.
 XX PR 14-AUG-2000; 2000US-0224519.
 XX PR 14-AUG-2000; 2000US-0225213.
 XX PR 14-AUG-2000; 2000US-0225214.
 XX PR 14-AUG-2000; 2000US-0225266.
 XX PR 14-AUG-2000; 2000US-0225267.
 XX PR 14-AUG-2000; 2000US-0225268.
 XX PR 14-AUG-2000; 2000US-0225270.
 XX PR 14-AUG-2000; 2000US-0225447.
 XX PR 14-AUG-2000; 2000US-0225757.
 XX PR 14-AUG-2000; 2000US-0225758.
 XX PR 14-AUG-2000; 2000US-0225759.
 XX PR 18-AUG-2000; 2000US-0226279.
 XX PR 22-AUG-2000; 2000US-0226681.
 XX PR 22-AUG-2000; 2000US-0226686.
 XX PR 22-AUG-2000; 2000US-0227182.
 XX PR 23-AUG-2000; 2000US-0227009.
 XX PR 30-AUG-2000; 2000US-0228924.
 XX PR 01-SEP-2000; 2000US-0229287.
 XX PR 01-SEP-2000; 2000US-0229343.
 XX PR 01-SEP-2000; 2000US-0229344.
 XX PR 01-SEP-2000; 2000US-0229345.
 XX PR 05-SEP-2000; 2000US-0229509.
 XX PR 05-SEP-2000; 2000US-0229513.
 XX PR 06-SEP-2000; 2000US-0230437.
 XX PR 06-SEP-2000; 2000US-0230438.
 XX PR 08-SEP-2000; 2000US-0231242.
 XX PR 08-SEP-2000; 2000US-0231243.
 XX PR 08-SEP-2000; 2000US-0231244.
 XX PR 08-SEP-2000; 2000US-0231413.
 XX PR 08-SEP-2000; 2000US-0231414.
 XX PR 08-SEP-2000; 2000US-0232080.
 XX PR 08-SEP-2000; 2000US-0232081.
 XX PR 12-SEP-2000; 2000US-0231968.
 XX PR 14-SEP-2000; 2000US-0232397.
 XX PR 14-SEP-2000; 2000US-0232398.
 XX PR 14-SEP-2000; 2000US-0232399.
 XX PR 14-SEP-2000; 2000US-0232400.
 XX PR 14-SEP-2000; 2000US-0232401.
 XX PR 14-SEP-2000; 2000US-0233063.
 XX PR 14-SEP-2000; 2000US-0233064.
 XX PR 14-SEP-2000; 2000US-0233065.
 XX PR 21-SEP-2000; 2000US-0234223.
 XX PR 21-SEP-2000; 2000US-0234274.
 XX PR 25-SEP-2000; 2000US-0234997.

PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 29-SEP-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-024617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 11-DEC-2000; 2000US-0251990.
PR 05-JAN-2001; 2001US-0259678.

XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
DR N-PSDB; AAL02047.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Claim 11; SEQ ID NO 4735; 1297pp + Sequence listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a protein of the invention.
XX
SQ Sequence 120 AA;

Query Match 11.1%; Score 9; DB 22; Length 120;
Best Local Similarity 100.0%; Pred. No. 0.14; Mismatches 0; Gaps 0;
Matches 9; Conservative 0; Indels 0;

Qy 20 LGDRARLCL 28
|||||||
Db 30 LGDRARLCL 38

Search completed: May 29, 2003, 15:30:40
Job time : 71 secs